Skip to content

The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body

The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00910702
Enrollment
15
Registered
2009-06-01
Start date
2009-05-31
Completion date
2013-03-31
Last updated
2013-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Detachment

Keywords

retinal detachment, vitreous body substitute

Brief summary

The purpose of this study is to determine the feasibility, primary safety and efficacy of foldable capsular vitreous body (FCVB) in the treatment of retinal detachment.

Detailed description

Pars plana vitrectomy (PPV) has been one of the most important ophthalmic surgeries for treating a number of blinding diseases by removing and replacing the diseased vitreous body. Current clinic vitreous substitute cannot mimic the natural vitreous which is unable to regenerate after surgery. We have devised a novel foldable capsular vitreous body (FCVB) consisting of a vitreous-like capsule with a tube-valve system, and demonstrated it could finely mimic the morphology and restore main physiological function of the natural vitreous body in our previous study.

Interventions

the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB) after PPV

Sponsors

Sun Yat-sen University
CollaboratorOTHER
GuangZhou WeiShiBo Biotechnology Co., ltd
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Refractive error less than ±3D 2. Visual acuity worse than finger count 3. Ocular perforating injuries, traumatic retinal detachment, giant retinal tear with PVR, serious than grade D PVR, ocular axial length is 16 to 25mm 4. Signed the informed consent form

Exclusion criteria

1. Serious heart, lung, liver and kidney dysfunction 2. Serious eye inflammation 3. Silicone oil filled eyes 4. The contralateral eye is non-functional 5. Patients with diseases that the researchers consider not suitable participated in this clinical trial

Design outcomes

Primary

MeasureTime frameDescription
Complete retinal reattach rate at the three years after implantation of the silicone-filled FCVBthree years after implantation of the FCVBFCVBs filled with balanced salt solution (BSS) were removed from all 11 cases, however, the risk of retinal redetachment and blindness rises after earlier FCVB removal. Approved by the Sun Yat-sen University Medical Ethics Committee, the removal of the FCVB will be decided by doctors depending on the conditions of eye. The eyes implanted with the silicone oil-filled FCVB are still under observation.

Secondary

MeasureTime frameDescription
visual acuity, intraocular pressure, axial length, ocular inflammatory response, the number of corneal endothelial, anterior chamber angle and ciliary body change, morphological changes of the ocular and FCVB.Before surgery, 3days,1 week, 2 weeks, 4 weeks, 8 weeks, 3 months, 6 months, 9 months, 1 year, 1.5 years, 2 years, 2.5 years and 3 years after surgery, and 3 months after the removal of the FCVBFCVBs filled with BSS were removed from all 11 cases, however, the risk of retinal redetachment and blindness rises after earlier FCVB removal. Approved by the Sun Yat-sen University Medical Ethics Committee, the removal of the FCVB will be decided by doctors depending on the conditions of eye. The eyes implanted with the FCVB and silicone oil are still under observation.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026